Literature DB >> 10073983

Lipid and apolipoprotein predictors of atherosclerosis in youth: apolipoprotein concentrations do not materially improve prediction of arterial lesions in PDAY subjects. The PDAY Research Group.

D L Rainwater1, C A McMahan, G T Malcom, W D Scheer, P S Roheim, H C McGill, J P Strong.   

Abstract

We compared serum lipid and apolipoprotein predictors of atherosclerosis in cases from the multicenter study, Pathobiological Determinants of Atherosclerosis in Youth (PDAY). The lipid measures included HDL cholesterol (HDL-C) and non-HDL-C, and the apolipoprotein measures included concentrations of apoA1, apoB, and Lp(a), and sizes of the apo(a) proteins. We tested whether the apolipoprotein measures predicted atherosclerotic lesions as well as the more traditional lipid measures. We estimated extent of lesions as fatty streaks or raised lesions (fibrous plaques, complicated or calcified lesions) in 3 sites: thoracic aorta, abdominal aorta, and right coronary artery. Neither apoA1 nor apoB measures were as strongly or consistently correlated with extent of lesions as the corresponding lipid measure (HDL-C and non-HDL-C, respectively). Beyond the basic model that included sex, age, race, smoking status, hypertension, and the lipid measures, apoA1 and apoB added only an average 1.3% increased explanatory ability to the model, whereas HDL-C plus non-HDL-C added an average 2.5%. The results suggest that the traditional lipid measures are more useful than apolipoprotein measures for detecting young persons at high risk of precocious atherosclerosis. Because of large racial differences, the two Lp(a)-related measures, Lp(a) concentrations and apo(a) size, were evaluated in blacks and whites separately. Under these circumstances, neither of the Lp(a)-related measures was strongly or consistently correlated with extent of lesions.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10073983     DOI: 10.1161/01.atv.19.3.753

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  8 in total

Review 1.  Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.

Authors:  Richard Kones
Journal:  Vasc Health Risk Manag       Date:  2013-10-21

2.  Cardiovascular Risk in Children and Adolescents with Type 1 and Type 2 Diabetes Mellitus.

Authors:  Sheela N Magge
Journal:  Curr Cardiovasc Risk Rep       Date:  2012-09-25

3.  Triglyceride to HDL-C ratio and increased arterial stiffness in children, adolescents, and young adults.

Authors:  Elaine M Urbina; Philip R Khoury; Connie E McCoy; Lawrence M Dolan; Stephen R Daniels; Thomas R Kimball
Journal:  Pediatrics       Date:  2013-03-04       Impact factor: 7.124

4.  Relationship of Apolipoproteins with Subclinical Cardiovascular Risk in Youth.

Authors:  Madeline A Czeck; Elise F Northrop; Nicholas G Evanoff; Donald R Dengel; Kyle D Rudser; Aaron S Kelly; Justin R Ryder
Journal:  J Pediatr       Date:  2020-08-11       Impact factor: 4.406

5.  Prediction of 10-year risk of hard coronary events among Saudi adults based on prevalence of heart disease risk factors.

Authors:  Muhammad Adil Soofi; Mostafa Adel Youssef
Journal:  J Saudi Heart Assoc       Date:  2015-03-26

Review 6.  The current state of dyslipidemia in Korean children and adolescents and its management in clinical practice.

Authors:  Jung Sub Lim
Journal:  Ann Pediatr Endocrinol Metab       Date:  2013-03-31

7.  Temporal trends in lipid testing among children and adolescents: A population based study.

Authors:  Swetha Sriram; Jennifer L St Sauver; Debra J Jacobson; Chun Fan; Brian A Lynch; Valeria Cristiani; Iftikhar J Kullo; Aida N Lteif; Seema Kumar
Journal:  Prev Med Rep       Date:  2017-11-08

8.  Triglyceride and cardiovascular risk: A critical appraisal.

Authors:  Awadhesh Kumar Singh; Ritu Singh
Journal:  Indian J Endocrinol Metab       Date:  2016 Jul-Aug
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.